Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia
Cooper Quartermaine(The Ohio State University Wexner Medical Center), Daniel Addison(The Ohio State University Wexner Medical Center), Tracy Wiczer(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jennifer A. Woyach(The Ohio State University), Patrick Ruz(The Ohio State University Wexner Medical Center), Kerry A. Rogers(The Ohio State University), Sujay Kalathoor(The Ohio State University Wexner Medical Center), Satyam Krishan(University of Oklahoma Medical Center), Seema A. Bhat(The Ohio State University), Michael R. Grever(Johns Hopkins University), Adnan Shaaban(The Ohio State University Wexner Medical Center), Michael G. Fradley(University of South Florida), Farrukh T. Awan(The Ohio State University), Aneeq Yasin(The Ohio State University Wexner Medical Center), Adam S. Kittai(The Ohio State University Wexner Medical Center), John C. Byrd(University of Cincinnati), Tyler Dickerson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Alma Habib(The Ohio State University), Onaopepo Kola‐Kehinde(The Ohio State University Wexner Medical Center), Mussammat Ferdousi(The Ohio State University Wexner Medical Center), Sanam Ghazi(The Ohio State University Wexner Medical Center)
Cited by 107
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia
|The Journal of Experimental Medicine|2001|1.1k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890